How prolonged exposure therapy helps people with PTSD.
Official title: Mechanisms Underlying Efficacy of Prolonged Exposure
Run by Massachusetts General Hospital · NCT05788302 · Data updated 2026-11-12
This project will see if brain activity, bodily responses, and symptom reports change across 10 sessions of Prolonged Exposure and predict improvement in adults with PTSD.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | April 1, 2023 |
| Main results expected | March 1, 2027 |
| Study ends | December 1, 2027 |
| Registry record updated | November 13, 2025 |
| Trial ID | NCT05788302 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older who meet DSM-5 criteria for PTSD, are interested in starting Prolonged Exposure, and are medically and psychiatrically stable (including stable psychotropic medication for at least two months) are the intended participants.
✕Probably not a fit
Individuals with current or past psychotic disorders, recent bipolar manic/mixed episodes, severe traumatic brain injury or major neurological problems, active moderate-or-greater substance use disorder, active safety risk, absence of memory for the traumatic event, or who have already received more than two PE sessions are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Up to 50 people will be screened with the goal of 15 participants completing a standard 10-session Prolonged Exposure (PE) program; participants must meet DSM-5 criteria for PTSD and be interested in starting PE. During each 60-minute PE session participants will wear a NINscan device to record skin conductance, heart rate, facial EMG, and lateral prefrontal cortex (LPFC) activity, and will complete multimodal assessment batteries at pre-treatment, mid-treatment (after session 5), post-treatment (after session 10), and one-month follow-up. The primary outcome is change in PTSD symptoms on the CAPS-5; secondary outcomes include self-reported symptom change, premature treatment dropout, and changes in psychophysiological and LPFC measures during script-driven imagery. The project aims to identify pretreatment predictors and mechanistic markers that change with PE to inform personalization and theoretical models of exposure therapy.
Why it matters
Potential benefit: If successful, the results could help clinicians predict who will benefit from PE and tailor exposure therapy to improve patient outcomes.
How similar studies have gone: Prior studies have found links between physiological or neural markers and PTSD treatment response, but longitudinal, session-level multimodal recording during PE is relatively novel and remains pilot in nature.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 or older 2. Meeting diagnostic criteria for PTSD as defined by DSM-5 assessed by the Diagnostic Interview for Anxiety, Mood, and Obsessive-compulsive and related Psychiatric Disorders (DIAMOND), and 3. Interest in starting PE Exclusion Criteria: 1. Current or past history of schizophrenic or other psychotic disorders, 2. Untreated Bipolar Disorder or a history of a manic/mixed episode within the last 6 months, 3. Severe traumatic brain injury, 4. Major neurological problems, 5. Current substance use disorder of moderate or greater severity assessed by the DIAMOND, 6. Active risk to self or others, 7. Current participation in therapy other than present-centered supportive therapy, 8. Previously received \> 2 sessions of Prolonged Exposure, and 9. Having no memory of their traumatic event. 10. For participants who are currently prescribed psychotropic medication, they will be eligible for the study provided medication use has been stable for 2 months prior to enrollment and remains stable throughout participation
Where it's running
-
Mgh
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Amanda W Baker, Ph.D. — Massachusetts General Hospital
- Study coordinator: Amanda W Baker, Ph.D.
- Email: AWBAKER1@PARTNERS.ORG
- Phone: 617-643-6703
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anger, Social Thinking, and PTSD in French Veterans
This study tests whether PTSD in former French military personnel is linked to higher anger through changes in social thinking abilities.
-
TSND-201 treatment for PTSD in adults
This study tests two doses of TSND-201 or placebo to see if it helps adults with PTSD.
-
Long-term outcomes after Hyperbaric Oxygen Therapy in veterans with TBI, PCS, or PTSD
This study tests whether benefits from HBOT persist over time for veterans with brain injury or related conditions.
-
SEE FAR CBT for Adults With PTSD
This 12-week, one-on-one SEE FAR CBT program tests a trauma-focused therapy to see if PTSD symptoms improve in adults 18 and older.
-
Brief SEE FAR CBT: a short, focused therapy for adults with PTSD
A 6-session Brief SEE FAR CBT treatment is tested against usual dynamic psychotherapy for adults with PTSD to see if it reduces symptoms.
-
MDMA Therapy for PTSD in Veterans
This phase 2 study tests a fixed 120 mg dose of MDMA, followed by a 60 mg supplemental dose, plus therapy, to see if it helps adults who are veterans with PTSD.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.